A complete reference guide to research peptides sourced by FenaLife Labs. Each entry covers mechanism of action, primary research application, and documented dosage ranges from preclinical and clinical literature. All compounds are for laboratory and research use only.
Use our Peptide Reconstitution Calculator to calculate exact bacteriostatic water volumes for any compound listed here.
GLP-1, GIP & Metabolic Peptides
| Compound |
Mechanism |
Primary Research Area |
Typical Research Dosage |
| Semaglutide |
GLP-1 receptor agonist; resists DPP-4 degradation via albumin-bound C18 fatty chain |
Weight reduction, glucose metabolism, cardiovascular biology, appetite regulation |
0.25–2.4 mg weekly SC (STEP/SUSTAIN trials) |
| Tirzepatide |
Dual GIP + GLP-1 receptor agonist; C20 fatty diacid modification |
Body composition, adipose tissue browning, insulin sensitivity, obesity models |
5–15 mg weekly SC (SURMOUNT trials) |
| Retatrutide |
Triple GLP-1 / GIP / Glucagon receptor agonist |
Aggressive fat reduction, energy expenditure, hepatic fat, lipid metabolism |
4–12 mg weekly SC (Phase 2 trials) |
| Cagrilintide |
Long-acting amylin analog; acts on amylin receptors in hypothalamus |
Satiety signaling, appetite suppression; often studied in combination with semaglutide (CagriSema) |
0.3–4.5 mg weekly SC (SCALE trials) |
| Survodutide |
Dual GLP-1 / Glucagon receptor agonist |
Fatty liver (MASH/NASH) research, weight reduction, energy expenditure |
0.6–6 mg weekly SC (Phase 2 MASH trials) |
| AOD9604 |
Synthetic fragment of hGH C-terminus (176-191); stimulates lipolysis, inhibits lipogenesis |
Fat metabolism, adipose reduction, bone repair; no IGF-1 elevation unlike full hGH |
250–500 mcg/day SC in human studies; 0.5 mg/kg in rodent models |
| 5-Amino-1MQ |
NNMT inhibitor; activates SAM cycle, promotes fat cell browning and energy expenditure |
Obesity research, metabolic rate, adipogenesis inhibition, insulin sensitivity |
50–100 mg/kg in mouse studies; oral bioavailability research ongoing |
| Adipotide (FTTP) |
Proapoptotic peptide targeting vasculature of white adipose tissue |
Fat depot reduction, obesity models; notable for targeted adipose cell apoptosis |
0.57 mg/kg/day SC in primate studies over 28 days |
Growth Hormone & Anabolic Peptides
| Compound |
Mechanism |
Primary Research Area |
Typical Research Dosage |
| Ipamorelin |
Selective GHSR-1a agonist; pulsatile GH release without cortisol/prolactin elevation |
GH regulation, body composition, lean mass, pituitary biology |
200–300 mcg SC per injection (human studies) |
| CJC-1295 with DAC |
GHRH analog with Drug Affinity Complex; extends half-life to ~8 days via albumin binding |
Sustained GH elevation, body composition, IGF-1 research |
1–2 mg SC weekly in research protocols |
| CJC-1295 without DAC |
GHRH analog; shorter half-life (~30 min); produces natural pulsatile GH pattern |
GH pulsatility research; often combined with Ipamorelin |
100–300 mcg SC per injection |
| Sermorelin |
Synthetic GHRH(1-29); stimulates pituitary to produce and secrete GH |
GH deficiency models, anti-aging, body composition, sleep quality research |
200–500 mcg SC at bedtime in human protocols |
| Tesamorelin |
Stabilized GHRH analog (trans-3-hexenoic acid); FDA-approved for HIV lipodystrophy |
Visceral fat reduction, GH axis research, cognitive function in GH-deficient models |
2 mg SC daily (FDA-approved dose); rodent: 100–300 mcg/kg |
| GHRP-6 |
Hexapeptide; GHSR agonist; also stimulates ghrelin and appetite |
GH secretion, appetite stimulation, cardioprotection in ischemia models |
100–300 mcg SC per injection; notable appetite stimulation at higher doses |
| Hexarelin |
Synthetic hexapeptide GHSR agonist; potent GH releaser; also binds CD36 receptors |
GH secretion, cardioprotection, heart failure models, atherosclerosis research |
2 mcg/kg SC in human studies; 80–160 mcg/kg in rodent models |
| IGF-1 LR3 |
Modified IGF-1 analog; extended half-life ~20h; activates IGF-1R, PI3K/Akt, MAPK |
Muscle protein synthesis, satellite cell activation, hypertrophy, lean mass preservation |
20–120 mcg/day SC in rodent studies; 50–200 ng/mL in vitro |
| PEG MGF |
PEGylated mechano growth factor (IGF-1 splice variant); activates muscle stem cells |
Muscle repair, satellite cell activation, recovery from mechanical damage |
200–400 mcg SC 2–3x per week in research protocols |
| MGF |
Mechano growth factor; local IGF-1 splice variant; activates quiescent muscle stem cells |
Muscle hypertrophy, repair after injury, satellite cell biology |
100–200 mcg IM per injection; short half-life (~minutes unPEGylated) |
| KisspeptIn-10 |
Endogenous neuropeptide; activates GnRH neurons via KISS1R; regulates HPG axis |
Reproductive biology, LH/FSH secretion, fertility research, puberty timing models |
1 nmol/kg IV bolus; 1–10 mcg/kg SC in rodent studies |
Tissue Repair & Recovery Peptides
| Compound |
Mechanism |
Primary Research Area |
Typical Research Dosage |
| BPC-157 |
FAK-paxillin pathway; nitric oxide modulation; VEGFR2-Akt-eNOS angiogenesis signaling |
Tendon/ligament repair, muscle healing, gut mucosal protection, nervous system research |
10–15 mcg/kg SC or IP in rodent models (~1–2 mg/day equivalent) |
| TB-500 (Thymosin Beta-4) |
Actin sequestration; regulates cell migration and tissue remodeling |
Wound healing, muscle fiber repair, cardiovascular tissue, inflammation reduction |
2–5 mg SC per injection in rodent and equine studies |
| GHK-Cu |
Copper-binding tripeptide; activates collagen synthesis, angiogenesis, fibroblast signaling |
Skin regeneration, wound healing, collagen production, anti-inflammatory, hair follicle |
1–10 mg/kg rodent studies; topical 0.5–2% concentrations widely studied |
| AHK-Cu |
Alanine-histidine-lysine tripeptide copper complex; hair follicle activation |
Hair growth research, follicle stimulation, scalp tissue repair |
0.1–1% topical in hair growth research; SC at 0.5–2 mg/kg in animal models |
| LL37 |
Human cathelicidin antimicrobial peptide; modulates innate immunity and wound healing |
Wound healing, antimicrobial research, skin barrier function, immune modulation |
1–10 mcg/mL in vitro; 1–5 mg/kg topical or SC in rodent wound models |
| KPV |
Tripeptide (Lys-Pro-Val) from alpha-MSH C-terminus; NF-κB pathway inhibitor |
Gut inflammation, IBD models, skin inflammatory conditions, wound healing |
100–500 mcg/day in rodent colitis models |
| TBF (Thymosin Beta-4 Sulfoxide) |
Oxidized form of Thymosin Beta-4; may have distinct anti-inflammatory properties |
Inflammation resolution, wound healing, recovery research |
2–15 mg per injection SC in research protocols (varies by study) |
| Thymalin |
Thymic peptide preparation; stimulates T-cell maturation and immune regulation |
Immune function, thymic biology, aging-related immune decline, longevity research |
5–20 mg SC or IM per course in Eastern European clinical research |
Cognitive, Neuroprotective & CNS Peptides
| Compound |
Mechanism |
Primary Research Area |
Typical Research Dosage |
| Semax |
Synthetic ACTH(4-7) analog; upregulates BDNF and NGF; HGF/c-Met activation |
Neuroprotection, cognitive function, stroke recovery, anxiety and stress response |
100–300 mcg intranasal per dose (Russian clinical research) |
| Selank |
Synthetic tuftsin analog; modulates GABA, serotonin, BDNF; anxiolytic |
Anxiety, stress response, memory, learning, immune modulation |
250–500 mcg intranasal; 100–300 mcg/kg SC in rodent models |
| DSIP (Delta Sleep Inducing Peptide) |
Nonapeptide that modulates sleep architecture; interacts with opioid and GHRH systems |
Sleep quality research, circadian rhythm biology, stress and neuroendocrine regulation |
25 nmol/kg IV in human research; 30–60 nmol/kg in rodent models |
| Pinealon |
Tripeptide from pineal gland (Glu-Asp-Arg); neuroprotective; modulates melatonin-related pathways |
Neuroprotection, aging-related cognitive decline, retinal research, longevity |
10–50 mcg/kg in animal studies; topical eye drop formulations studied |
| Dermorphin |
Heptapeptide mu-opioid receptor agonist; 1000x more potent than morphine |
Opioid receptor biology, pain research, addiction models |
10–100 nmol/kg in rodent nociception studies; extremely potent, nanogram-range active |
| VIP (Vasoactive Intestinal Peptide) |
Neuropeptide; activates VPAC1/VPAC2 receptors; broad anti-inflammatory and vasodilatory effects |
Inflammation, immune modulation, pulmonary research, circadian rhythm, gut motility |
25–50 pmol/kg/min IV infusion in human research; 1–10 nmol SC in rodent studies |
| PT-141 (Bremelanotide) |
Melanocortin MC3R/MC4R agonist; central hypothalamic dopamine activation |
Sexual arousal and behavior research, melanocortin CNS circuitry |
1.25–1.75 mg SC per dose in clinical studies (FDA-approved at 1.75 mg) |
| Oxytocin Acetate |
Hypothalamic neuropeptide; oxytocin receptor agonist in brain and peripheral tissue |
Social bonding, trust and prosocial behavior, stress response, autism spectrum models |
24 IU intranasal per dose in human research |
| Melanotan-1 (MT-1) |
Alpha-MSH analog; activates MC1R; promotes melanogenesis with minimal CNS activity |
Skin pigmentation research, photoprotection, UV damage models |
0.5–1 mg SC per dose in human studies; selective MC1R vs MT-2 |
| Snap-8 |
Octapeptide SNAP-25 competitor; reduces neuromuscular signal at synapse |
Facial expression muscle relaxation research; topical neurocosmetic studies |
4–10% concentration in topical formulations studied; in vitro at 50–500 mcg/mL |
| PNC-27 |
p53 C-terminus peptide analog; selectively induces apoptosis in cancer cell lines |
Oncology research, tumor cell apoptosis, p53 pathway biology |
10–50 mcg/mL in vitro; rodent tumor models at 5–15 mg/kg SC |
Mitochondrial, Longevity & Anti-Aging Peptides
| Compound |
Mechanism |
Primary Research Area |
Typical Research Dosage |
| MOTS-c |
Mitochondrial-derived peptide; AMPK activation; improves mitochondrial biogenesis |
Metabolic health, exercise physiology, skeletal muscle energy, aging biology |
5–10 mg/kg SC in mouse models; exercise-mimetic effects studied |
| SS-31 (Elamipretide) |
Mitochondria-targeted tetrapeptide; binds cardiolipin, reduces ROS |
Mitochondrial dysfunction, heart failure, kidney disease, oxidative stress |
0.05–5 mg/kg SC in animal models; 0.005–0.25 mg/kg IV in human studies |
| Epithalon (Epitalon) |
Tetrapeptide (Ala-Glu-Asp-Gly); activates telomerase; modulates melatonin secretion |
Telomere biology, longevity, circadian rhythm, anti-aging research |
5–10 mg SC or IV daily for 10-day courses in Eastern European research |
| Thymosin Alpha-1 (TA-1) |
N-terminal fragment of prothymosin alpha; potent immune modulator; TLR/NK cell activation |
Immune enhancement, cancer immunology, antiviral research, sepsis models |
1.6–6 mg SC biweekly in clinical research; FDA breakthrough designation in COVID studies |
| Cartalax |
Tripeptide from cartilage; promotes proteoglycan synthesis and chondrocyte activity |
Cartilage regeneration, joint health research, aging-related tissue degeneration |
5–20 mcg/kg SC in rodent cartilage studies |
| Pinealon |
Pineal-derived tripeptide; neuroprotective; free radical scavenging |
Brain aging, neurodegeneration, retinal preservation, longevity research |
10–50 mcg/kg in animal studies |
| NAD+ |
Essential coenzyme for cellular energy metabolism; sirtuin activation; DNA repair support |
Cellular aging, epigenetic regulation, metabolic function, neurodegeneration research |
250–1000 mg IV per session in human research; oral: 250–500 mg/day |
| ACE-031 |
Soluble form of activin receptor type IIB; inhibits myostatin and related ligands |
Muscle wasting disorders, sarcopenia, Duchenne muscular dystrophy models |
0.02–3 mg/kg SC biweekly in Phase 1/2 trials (Acceleron Pharma data) |
| ARA290 (Cibinetide) |
Erythropoietin-derived peptide; activates innate repair receptor; tissue-protective without hematopoietic effects |
Neuropathy, inflammation, tissue protection, sarcoidosis research |
4–16 mg/day SC in human trials (Phase 2 neuropathy studies) |
Immune & Antimicrobial Peptides
| Compound |
Mechanism |
Primary Research Area |
Typical Research Dosage |
| Gonadorelin |
Synthetic GnRH decapeptide; stimulates LH and FSH release from pituitary |
Reproductive endocrinology, fertility research, HPG axis regulation, testosterone production |
100 mcg IV/SC bolus in human diagnostic studies; pulsatile infusion at 5–20 mcg/90 min |
| VIP |
See Cognitive section above — also prominent in immune regulation research |
Anti-inflammatory, autoimmune models, pulmonary fibrosis, gut immunity |
See above |
Skin, Hair & Cosmetic Research Peptides
| Compound |
Mechanism |
Primary Research Area |
Typical Research Dosage |
| GHK-Cu |
See Tissue Repair section — also extensively studied in dermatology |
Skin regeneration, collagen, hair follicle stimulation |
Topical 0.5–2%; SC 1–5 mg/kg |
| AHK-Cu |
Alanine-His-Lys copper complex; hair follicle activation and anchoring |
Hair regrowth research, alopecia models, follicle biology |
0.1–1% topical formulations; 0.5–2 mg/kg SC in rodent models |
| Snap-8 |
See Cognitive section — neurocosmetic research for expression lines |
Topical muscle relaxation research; wrinkle reduction studies |
4–10% topical concentration |
| Glutathione |
Endogenous tripeptide antioxidant (Glu-Cys-Gly); reduces oxidative stress; melanin pathway inhibition |
Oxidative stress, skin brightening research, liver function, detoxification biology |
600–1200 mg IV per session; oral 250–1000 mg/day in human research |
Other Compounds
| Compound |
Type |
Research Area |
Notes |
| Lipo-C |
Lipotropic compound blend (methionine, inositol, choline, B12) |
Lipid metabolism, hepatic fat reduction, energy and fat mobilization |
Typically 1–2 mL IM injection in clinical protocols; not a single peptide |
| ALCAR (L-Carnitine Acetyl) |
Acetylated form of L-carnitine; crosses blood-brain barrier; mitochondrial fatty acid transport |
Mitochondrial energy, cognitive function, neuroprotection, fat oxidation research |
500–2000 mg oral/day; 500 mg IV in human cognitive research |
| B12 |
Cyanocobalamin / methylcobalamin; essential for neurological function and red blood cell synthesis |
Nerve function, energy metabolism, methylation, homocysteine research |
1000 mcg IM weekly (deficiency); 5000 mcg IM for neurological protocols |
| EPO (Erythropoietin) |
Glycoprotein hormone; stimulates red blood cell production via EPO receptor |
Anemia research, oxygen delivery, erythropoiesis biology, endurance physiology models |
50–300 IU/kg SC 3x/week in clinical anemia research |
Research Combinations
Several commonly studied compound combinations are available as pre-made blends:
| Combination |
Components |
Research Purpose |
| BPC + TB Stack |
BPC-157 5mg + TB-500 5mg (or 10mg + 10mg) |
Synergistic tissue repair — BPC-157 targets angiogenesis/gut; TB-500 targets actin/cell migration. Sometimes called the “Wolverine Stack.” |
| CagriSema |
Cagrilintide 5mg + Semaglutide 5mg (or 10mg + 10mg) |
Dual appetite suppression via amylin + GLP-1 pathways; studied for additive weight reduction |
| KLOW |
GHK-Cu 50mg + TB-500 10mg + BPC-157 10mg + KPV 10mg |
Multi-compound anti-inflammatory and recovery blend |
| GLOW |
BPC-157 10mg + GHK-Cu 50mg + TB-500 10mg |
Tissue repair and skin/collagen research combination |
| MIC Lipo-C + B12 |
Methionine + Inositol + Choline + B12 |
Lipotropic metabolism support research; liver health and fat mobilization |
| CJC-1295 + Ipamorelin |
CJC-1295 (with or without DAC) + Ipamorelin |
Synergistic GH release — GHRH analog increases somatotrophs, Ipamorelin triggers release via GHSR |
| Retatrutide + Tirzepatide |
Retatrutide 20mg + Tirzepatide 40mg |
Combined triple + dual agonism; emerging research in extreme metabolic intervention models |
Equipment & Reconstitution Supplies
Need help mixing? Use our Universal Peptide Reconstitution Calculator →
All compounds are sold by FenaLife Labs for in vitro and preclinical research purposes only. Not approved for human use. Nothing here constitutes medical advice. Researchers are responsible for compliance with applicable regulations.
